Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus

Citation
E. Balada et al., Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus, SC J RHEUM, 30(4), 2001, pp. 235-241
Citations number
41
Categorie Soggetti
Rheumatology,"da verificare
Journal title
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
ISSN journal
03009742 → ACNP
Volume
30
Issue
4
Year of publication
2001
Pages
235 - 241
Database
ISI
SICI code
0300-9742(2001)30:4<235:AACTTD>2.0.ZU;2-Q
Abstract
Objective: To evaluate the correlation between antiphosphatidylethanolamine antibodies (aPE) and some antiphospholipid antibodies (aPL)-related clinic al manifestations in patients with systemic lupus erythematosus (SLE). Methods: Patients with SLE (n=217) were tested for the presence of aPE, ant icardiolipin antibodies (aCL), and lupus anticoagulant (LA). The prospectiv e aPL-related clinical manifestations studied were: thrombosis, thrombocyto penia, recurrent fetal losses, heart valvulopathies, hemolytic anemia, live do reticularis. and pulmonary hypertension. Results: A total of 109 SLE patients (50.23%) were IgG aPE-positive; 17.51% presented aPE as the sole autoantibody and had some clinical features of a PL-related clinical manifestations. IgG aPE were associated to the presence of heart valvulopathies (p = 0.002). A statistical difference was also rou nd when considering high levels of IgG aPE (O.D. > 0.600) in patients with livedo reticularis (p = 0.008). Conclusion: The evaluation of IgG aPE may allow us to detect some more pati ents with aPL-related clinical manifestations in the SLE population. aPE co rrelated particularly with valvulopathies and livedo reticularis.